Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-06-28

AUTHORS

Pasquale De Nardo, Magdalena Viscione, Angela Corpolongo, Rita Bellagamba, Giovanni Vennarecci, Giuseppe Maria Ettorre, Elisa Gentilotti, Chiara Tommasi, Emanuele Nicastri

ABSTRACT

BACKGROUND: Liver disease is the second cause of death among HIV patients receiving highly active antiretroviral therapy (HAART) in Europe. HIV patients have a high prevalence of chronic HBV (6-10%) and HCV (33%) co-infection, and accelerated progression of viral hepatitis. Furthermore, the long duration of both HIV and HCV diseases in the HAART era increases the risk of hepatocellular carcinoma. FINDINGS: We report the case of a 49 year -old HIV/HCV co-infected male patient who developed hepatocellular carcinoma. The patient underwent a partial hepatectomy, and a few months later was treated with transcatheter arterial chemoembolisation due to hepatocarcinoma recurrence. Two months later, advanced hepatocellular carcinoma was diagnosed and sorafenib therapy was initiated. The patient achieved partial response of the main lesions, complete regression of the smallest lesions and did not experience clinical progression during the 20-month follow-up period. During therapy with sorafenib, the patient was treated with HAART with good viral and immunological responses. We used the therapeutic drug monitoring to assess antiretroviral concentrations during co-administration of sorafenib. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines. No grade 3 or 4 toxicities were observed. At month 20 of treatment, new liver lesions with portal vein thrombosis were diagnosed. After 28 months of sorafenib therapy, the patient deceased for severe liver insufficiency. CONCLUSIONS: Sorafenib monotherapy demonstrated a marked delay in HCC disease progression in an HIV/HCV co-infected patient. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines, suggesting a possible interaction. More... »

PAGES

15-15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1750-9378-7-15

DOI

http://dx.doi.org/10.1186/1750-9378-7-15

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038034612

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22741810


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Nardo", 
        "givenName": "Pasquale", 
        "id": "sg:person.0674412415.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674412415.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Viscione", 
        "givenName": "Magdalena", 
        "id": "sg:person.01275614332.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275614332.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Corpolongo", 
        "givenName": "Angela", 
        "id": "sg:person.0622421657.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622421657.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bellagamba", 
        "givenName": "Rita", 
        "id": "sg:person.0647671457.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647671457.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416308.8", 
          "name": [
            "General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vennarecci", 
        "givenName": "Giovanni", 
        "id": "sg:person.0611306744.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611306744.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416308.8", 
          "name": [
            "General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ettorre", 
        "givenName": "Giuseppe Maria", 
        "id": "sg:person.01153514070.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153514070.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gentilotti", 
        "givenName": "Elisa", 
        "id": "sg:person.0623244161.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623244161.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tommasi", 
        "givenName": "Chiara", 
        "id": "sg:person.01045744574.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045744574.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy", 
          "id": "http://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS \u201cL. Spallanzani\u201d, via Portuense 292, 00149, Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicastri", 
        "givenName": "Emanuele", 
        "id": "sg:person.01160152235.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160152235.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-010-9669-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030541097", 
          "https://doi.org/10.1007/s12032-010-9669-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200969020-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037157538", 
          "https://doi.org/10.2165/00003495-200969020-00006"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-28", 
    "datePublishedReg": "2012-06-28", 
    "description": "\nBACKGROUND: Liver disease is the second cause of death among HIV patients receiving highly active antiretroviral therapy (HAART) in Europe. HIV patients have a high prevalence of chronic HBV (6-10%) and HCV (33%) co-infection, and accelerated progression of viral hepatitis. Furthermore, the long duration of both HIV and HCV diseases in the HAART era increases the risk of hepatocellular carcinoma.\nFINDINGS: We report the case of a 49\u2009year -old HIV/HCV co-infected male patient who developed hepatocellular carcinoma. The patient underwent a partial hepatectomy, and a few months later was treated with transcatheter arterial chemoembolisation due to hepatocarcinoma recurrence. Two months later, advanced hepatocellular carcinoma was diagnosed and sorafenib therapy was initiated. The patient achieved partial response of the main lesions, complete regression of the smallest lesions and did not experience clinical progression during the 20-month follow-up period. During therapy with sorafenib, the patient was treated with HAART with good viral and immunological responses. We used the therapeutic drug monitoring to assess antiretroviral concentrations during co-administration of sorafenib. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines. No grade 3 or 4 toxicities were observed. At month 20 of treatment, new liver lesions with portal vein thrombosis were diagnosed. After 28\u2009months of sorafenib therapy, the patient deceased for severe liver insufficiency.\nCONCLUSIONS: Sorafenib monotherapy demonstrated a marked delay in HCC disease progression in an HIV/HCV co-infected patient. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines, suggesting a possible interaction.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1750-9378-7-15", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1037008", 
        "issn": [
          "1750-9378"
        ], 
        "name": "Infectious Agents and Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "hepatocellular carcinoma", 
      "HIV patients", 
      "sorafenib therapy", 
      "HIV/HCV co-infected patients", 
      "international guidelines", 
      "HCV co-infected patients", 
      "HIV/HCV-co", 
      "transcatheter arterial chemoembolisation", 
      "HCC disease progression", 
      "active antiretroviral therapy", 
      "portal vein thrombosis", 
      "co-infected patients", 
      "recurrent hepatocellular carcinoma", 
      "advanced hepatocellular carcinoma", 
      "new liver lesions", 
      "severe liver insufficiency", 
      "therapeutic drug monitoring", 
      "sorafenib monotherapy", 
      "HCV-co", 
      "chronic HBV", 
      "HCV disease", 
      "HAART era", 
      "antiretroviral therapy", 
      "viral hepatitis", 
      "antiretroviral concentrations", 
      "partial response", 
      "vein thrombosis", 
      "male patients", 
      "liver insufficiency", 
      "liver disease", 
      "clinical progression", 
      "complete regression", 
      "case report", 
      "disease progression", 
      "high prevalence", 
      "main lesion", 
      "grade 3", 
      "immunological response", 
      "liver lesions", 
      "patients", 
      "month 20", 
      "drug monitoring", 
      "carcinoma", 
      "second cause", 
      "small lesions", 
      "therapy", 
      "partial hepatectomy", 
      "sorafenib", 
      "lesions", 
      "longer duration", 
      "progression", 
      "HAART", 
      "Ctrough", 
      "months", 
      "disease", 
      "treatment", 
      "possible interactions", 
      "guidelines", 
      "monotherapy", 
      "HCV", 
      "hepatitis", 
      "chemoembolisation", 
      "HBV", 
      "thrombosis", 
      "HIV", 
      "recurrence", 
      "hepatectomy", 
      "insufficiency", 
      "follow", 
      "prevalence", 
      "response", 
      "death", 
      "levels", 
      "risk", 
      "cause", 
      "minimum level", 
      "toxicity", 
      "duration", 
      "report", 
      "regression", 
      "years", 
      "period", 
      "cases", 
      "concentration", 
      "monitoring", 
      "delay", 
      "era", 
      "interaction", 
      "Europe", 
      "CO", 
      "HIV/HCV co-infected male patient", 
      "HCV co-infected male patient", 
      "co-infected male patient", 
      "arterial chemoembolisation", 
      "hepatocarcinoma recurrence", 
      "Fosamprenavir Ctrough"
    ], 
    "name": "Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report", 
    "pagination": "15-15", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038034612"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1750-9378-7-15"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22741810"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1750-9378-7-15", 
      "https://app.dimensions.ai/details/publication/pub.1038034612"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_559.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1750-9378-7-15"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-7-15'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-7-15'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-7-15'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1750-9378-7-15'


 

This table displays all metadata directly associated to this object as RDF triples.

228 TRIPLES      22 PREDICATES      125 URIs      114 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1750-9378-7-15 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1108
4 schema:author N2494627eb55d4b5b8e93f92cf12ea419
5 schema:citation sg:pub.10.1007/s12032-010-9669-y
6 sg:pub.10.2165/00003495-200969020-00006
7 schema:datePublished 2012-06-28
8 schema:datePublishedReg 2012-06-28
9 schema:description BACKGROUND: Liver disease is the second cause of death among HIV patients receiving highly active antiretroviral therapy (HAART) in Europe. HIV patients have a high prevalence of chronic HBV (6-10%) and HCV (33%) co-infection, and accelerated progression of viral hepatitis. Furthermore, the long duration of both HIV and HCV diseases in the HAART era increases the risk of hepatocellular carcinoma. FINDINGS: We report the case of a 49 year -old HIV/HCV co-infected male patient who developed hepatocellular carcinoma. The patient underwent a partial hepatectomy, and a few months later was treated with transcatheter arterial chemoembolisation due to hepatocarcinoma recurrence. Two months later, advanced hepatocellular carcinoma was diagnosed and sorafenib therapy was initiated. The patient achieved partial response of the main lesions, complete regression of the smallest lesions and did not experience clinical progression during the 20-month follow-up period. During therapy with sorafenib, the patient was treated with HAART with good viral and immunological responses. We used the therapeutic drug monitoring to assess antiretroviral concentrations during co-administration of sorafenib. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines. No grade 3 or 4 toxicities were observed. At month 20 of treatment, new liver lesions with portal vein thrombosis were diagnosed. After 28 months of sorafenib therapy, the patient deceased for severe liver insufficiency. CONCLUSIONS: Sorafenib monotherapy demonstrated a marked delay in HCC disease progression in an HIV/HCV co-infected patient. Fosamprenavir Ctrough was found under the minimum level recommended by international guidelines, suggesting a possible interaction.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N4f588d5278fa48cb87e31ebd0b93517d
14 N811c273fb9de4abe969963efb920e974
15 sg:journal.1037008
16 schema:keywords CO
17 Ctrough
18 Europe
19 Fosamprenavir Ctrough
20 HAART
21 HAART era
22 HBV
23 HCC disease progression
24 HCV
25 HCV co-infected male patient
26 HCV co-infected patients
27 HCV disease
28 HCV-co
29 HIV
30 HIV patients
31 HIV/HCV co-infected male patient
32 HIV/HCV co-infected patients
33 HIV/HCV-co
34 active antiretroviral therapy
35 advanced hepatocellular carcinoma
36 antiretroviral concentrations
37 antiretroviral therapy
38 arterial chemoembolisation
39 carcinoma
40 case report
41 cases
42 cause
43 chemoembolisation
44 chronic HBV
45 clinical progression
46 co-infected male patient
47 co-infected patients
48 complete regression
49 concentration
50 death
51 delay
52 disease
53 disease progression
54 drug monitoring
55 duration
56 era
57 follow
58 grade 3
59 guidelines
60 hepatectomy
61 hepatitis
62 hepatocarcinoma recurrence
63 hepatocellular carcinoma
64 high prevalence
65 immunological response
66 insufficiency
67 interaction
68 international guidelines
69 lesions
70 levels
71 liver disease
72 liver insufficiency
73 liver lesions
74 longer duration
75 main lesion
76 male patients
77 minimum level
78 monitoring
79 monotherapy
80 month 20
81 months
82 new liver lesions
83 partial hepatectomy
84 partial response
85 patients
86 period
87 portal vein thrombosis
88 possible interactions
89 prevalence
90 progression
91 recurrence
92 recurrent hepatocellular carcinoma
93 regression
94 report
95 response
96 risk
97 second cause
98 severe liver insufficiency
99 small lesions
100 sorafenib
101 sorafenib monotherapy
102 sorafenib therapy
103 therapeutic drug monitoring
104 therapy
105 thrombosis
106 toxicity
107 transcatheter arterial chemoembolisation
108 treatment
109 vein thrombosis
110 viral hepatitis
111 years
112 schema:name Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report
113 schema:pagination 15-15
114 schema:productId N640998610896469aa4e60cbdd28c804f
115 N8dea4486a1334fd59548331dab8dc2d3
116 Ncbb65b68a0724d2884e3e7be9ae13eb4
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038034612
118 https://doi.org/10.1186/1750-9378-7-15
119 schema:sdDatePublished 2021-12-01T19:26
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher Nee582af9d41a4e10b9584b809cc2d5b3
122 schema:url https://doi.org/10.1186/1750-9378-7-15
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N2494627eb55d4b5b8e93f92cf12ea419 rdf:first sg:person.0674412415.06
127 rdf:rest Nb62056c35dce4d3686a29245c0e82501
128 N33975c7b259d486aa206cabc5ebbd2ac rdf:first sg:person.0623244161.01
129 rdf:rest N6740e2c8ca5548f7bcede87d57dc5508
130 N3ccc15797963425f9b0476138c036354 rdf:first sg:person.0647671457.37
131 rdf:rest N4ff9182f1a33422f9bd07f99fe2c5c5e
132 N4cab1e2a381c4f55bb647fbac3245c32 rdf:first sg:person.01153514070.86
133 rdf:rest N33975c7b259d486aa206cabc5ebbd2ac
134 N4f588d5278fa48cb87e31ebd0b93517d schema:volumeNumber 7
135 rdf:type schema:PublicationVolume
136 N4ff9182f1a33422f9bd07f99fe2c5c5e rdf:first sg:person.0611306744.39
137 rdf:rest N4cab1e2a381c4f55bb647fbac3245c32
138 N640998610896469aa4e60cbdd28c804f schema:name pubmed_id
139 schema:value 22741810
140 rdf:type schema:PropertyValue
141 N6740e2c8ca5548f7bcede87d57dc5508 rdf:first sg:person.01045744574.20
142 rdf:rest N8e8bfe495c6f46439ad24b8f9fa23b0f
143 N811c273fb9de4abe969963efb920e974 schema:issueNumber 1
144 rdf:type schema:PublicationIssue
145 N8dea4486a1334fd59548331dab8dc2d3 schema:name doi
146 schema:value 10.1186/1750-9378-7-15
147 rdf:type schema:PropertyValue
148 N8e8bfe495c6f46439ad24b8f9fa23b0f rdf:first sg:person.01160152235.27
149 rdf:rest rdf:nil
150 N9ec6748c0be74e0ea74aaebed8a1b7c9 rdf:first sg:person.0622421657.38
151 rdf:rest N3ccc15797963425f9b0476138c036354
152 Nb62056c35dce4d3686a29245c0e82501 rdf:first sg:person.01275614332.39
153 rdf:rest N9ec6748c0be74e0ea74aaebed8a1b7c9
154 Ncbb65b68a0724d2884e3e7be9ae13eb4 schema:name dimensions_id
155 schema:value pub.1038034612
156 rdf:type schema:PropertyValue
157 Nee582af9d41a4e10b9584b809cc2d5b3 schema:name Springer Nature - SN SciGraph project
158 rdf:type schema:Organization
159 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
160 schema:name Medical and Health Sciences
161 rdf:type schema:DefinedTerm
162 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
163 schema:name Clinical Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical Microbiology
167 rdf:type schema:DefinedTerm
168 sg:journal.1037008 schema:issn 1750-9378
169 schema:name Infectious Agents and Cancer
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01045744574.20 schema:affiliation grid-institutes:grid.414603.4
173 schema:familyName Tommasi
174 schema:givenName Chiara
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045744574.20
176 rdf:type schema:Person
177 sg:person.01153514070.86 schema:affiliation grid-institutes:grid.416308.8
178 schema:familyName Ettorre
179 schema:givenName Giuseppe Maria
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153514070.86
181 rdf:type schema:Person
182 sg:person.01160152235.27 schema:affiliation grid-institutes:grid.414603.4
183 schema:familyName Nicastri
184 schema:givenName Emanuele
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160152235.27
186 rdf:type schema:Person
187 sg:person.01275614332.39 schema:affiliation grid-institutes:grid.414603.4
188 schema:familyName Viscione
189 schema:givenName Magdalena
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275614332.39
191 rdf:type schema:Person
192 sg:person.0611306744.39 schema:affiliation grid-institutes:grid.416308.8
193 schema:familyName Vennarecci
194 schema:givenName Giovanni
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611306744.39
196 rdf:type schema:Person
197 sg:person.0622421657.38 schema:affiliation grid-institutes:grid.414603.4
198 schema:familyName Corpolongo
199 schema:givenName Angela
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622421657.38
201 rdf:type schema:Person
202 sg:person.0623244161.01 schema:affiliation grid-institutes:grid.414603.4
203 schema:familyName Gentilotti
204 schema:givenName Elisa
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623244161.01
206 rdf:type schema:Person
207 sg:person.0647671457.37 schema:affiliation grid-institutes:grid.414603.4
208 schema:familyName Bellagamba
209 schema:givenName Rita
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647671457.37
211 rdf:type schema:Person
212 sg:person.0674412415.06 schema:affiliation grid-institutes:grid.414603.4
213 schema:familyName De Nardo
214 schema:givenName Pasquale
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674412415.06
216 rdf:type schema:Person
217 sg:pub.10.1007/s12032-010-9669-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1030541097
218 https://doi.org/10.1007/s12032-010-9669-y
219 rdf:type schema:CreativeWork
220 sg:pub.10.2165/00003495-200969020-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037157538
221 https://doi.org/10.2165/00003495-200969020-00006
222 rdf:type schema:CreativeWork
223 grid-institutes:grid.414603.4 schema:alternateName Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS “L. Spallanzani”, via Portuense 292, 00149, Rome, Italy
224 schema:name Clinical Department of Infectious Diseases, National Institute for Infectious Diseases IRCCS “L. Spallanzani”, via Portuense 292, 00149, Rome, Italy
225 rdf:type schema:Organization
226 grid-institutes:grid.416308.8 schema:alternateName General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy
227 schema:name General and Transplant Surgery, San Camillo-Forlanini Hospital, via Portuense 292, 00149, Rome, Italy
228 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...